|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
Jordanian Pharmaceutical Manufacturing (الشركة الاردنية لتصنيع الادوية )
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name Jordanian Pharmaceutical Manufacturing (الشركة الاردنية لتصنيع الادوية ) Headquarters Madaba - om al-amaad P.O.Box : 151 Amman 16197; Amman; West Zone; 16197 |
Status: Listed Legal Form: Other non-liability limited Operational Status: Operational ISIN CODE : JO4120411015 Financial Auditors: Arabian Profesional Group (2010) Total Employees: 522 Tel: 00962 6 4290744 |
|
Company Description |
|
The Jordanian Pharmaceutical Manufacturing Company PLC is a Jordan-based public shareholding company engaged in the manufacture and distribution of medicine, chemical, cosmetic, and pharmaceutical products. The Company is also involved in the trade of medical appliances. Its subsidiaries include Dallas Company for Natural Products (93.33%), Arajan Biotechnology Company (56.6), Sawagh Company (93.33%) and Algerian Jordanian Pharmaceutical Company (98%). |
Company Analysis |
| According to the Individual - Audited financial statement for the Year of 2011, total net operating revenues increased with 39.60%, from JOD 20,890.027 thousands to JOD 29,163.326 thousands. The results of the period decreased -30.46% reaching JOD 1,968.253 thousands at the end of the period against JOD 2,830.337 thousands last year. Return on equity (Net income/Total equity) went from 6.78% to 4.61%, the Return On Asset (Net income / Total Asset) went from 4.64% to 2.68% and the Net Profit Margin (Net Income/Net Sales) went from 13.55% to 6.75% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 72.03% compared to 46.18% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 2.42 to 2.97 when compared to the previous year. |
Key Executives |
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2011 Y (non-cons) |
2010 Y (non-cons) |
|
 | ||
| Audited | Audited | |
| ||
| Finglobe - MENA Spread Financial Statements | Finglobe - MENA Spread Financial Statements | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
73,464 |
61,009 |
| ||
Current Assets |
41,993 |
32,824 |
| ||
Total Liabilities |
30,760 |
19,273 |
| ||
Shareholders Equity |
42,704 |
41,736 |
| ||
Current Liabilities |
14,128 |
13,578 |
| ||
| * All the accounts are in JOD. | ||
Income Statement
| ||
Total Operating Revenue |
29,163 |
20,890 |
| ||
Net Profit (Loss) |
1,968 |
2,830 |
| ||
| * All the accounts are in JOD. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
2.68% |
4.64% |
| ||
Annualised Return on Assets (ROA) |
2.68% |
4.64% |
| ||
Return on Equity (ROE) |
4.61% |
6.78% |
| ||
Annualised Return on Equity (ROE) |
4.78% |
7.36% |
| ||
Return on Sales (ROS) |
6.75% |
13.55% |
| ||
Return on Capital |
0% |
0% |
| ||
Gross Profit Margin |
129.67% |
134.73% |
| ||
Operating Profit Margin |
0% |
0% |
| Efficiency Ratios | ||
| ||
Accounts Receivable Turnover |
1.13x |
0.93x |
| ||
Inventory Turnover |
2.98x |
2.97x |
| ||
Current asset turnover |
0.69x |
0.64x |
| ||
Fixed-asset turnover |
0.93x |
0.74x |
| ||
Asset Turnover |
0.40x |
0.34x |
| Valuation figures and ratios | ||
| ||
EBITDA |
423 |
429 |
| ||
Enterprise value |
51,998 |
43,580 |
| ||
Enterprise Value / EBITDA |
122.80 |
101.54 |
| ||
Bookvalue (BV) |
42,704 |
41,736 |
| ||
Net Cash |
-25,998 |
-14,980 |
| Liquidity Ratios | ||
| ||
Current Ratio |
297.22% |
241.74% |
| ||
Quick ratio |
227.91% |
189.9% |
| ||
Doom's day ratio |
33.7% |
31.62% |
| Leverage Ratios | ||
| ||
Leverage ratio |
172.03% |
146.18% |
| ||
Debt to equity |
72.03% |
46.18% |
| ||
Debt to total assets |
41.87% |
31.59% |
| ||
Long Term Debt to Capital |
28.03% |
12.01% |
| Market ratios | ||
| ||
Market Capitalization/EBITDA |
61.40 |
66.64 |
| ||
Market Cap / Net cash |
-1.00 |
-1.91 |
| Trend Ratios | ||
| ||
Revenue Trend |
139.6% |
92.18% |
| ||
Net Income Trend |
69.54% |
95.09% |
| ||
 |